UBS raised the firm’s price target on Elevance Health to $605 from $585 and keeps a Buy rating on the shares. Elevance Health posted Q1 EPS that was better than analyst estimates, driven by a better than expected medical loss ratio and offset by modestly higher SG&A, and raised its 2024 EPS outlook by 10c, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, April 18, 2024
- Elevance Health reports Medical membership totaled ~46.2M at March 31
- Elevance Health raises FY24 adjusted EPS view to greater than $37.20 per share
- Elevance Health reports Q1 adjusted EPS $10.64, consensus $10.53
- Notable companies reporting before tomorrow’s open
